These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36590299)

  • 1. Linking the gut microbiome to microglial activation in opioid use disorder.
    Antoine D; Venigalla G; Truitt B; Roy S
    Front Neurosci; 2022; 16():1050661. PubMed ID: 36590299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbes, microglia, and pain.
    Dworsky-Fried Z; Kerr BJ; Taylor AMW
    Neurobiol Pain; 2020; 7():100045. PubMed ID: 32072077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Gut-Microglia Connection: Implications for Central Nervous System Diseases.
    Wang Y; Wang Z; Wang Y; Li F; Jia J; Song X; Qin S; Wang R; Jin F; Kitazato K; Wang Y
    Front Immunol; 2018; 9():2325. PubMed ID: 30344525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Use, Gut Dysbiosis, Inflammation, and the Nervous System.
    Jalodia R; Abu YF; Oppenheimer MR; Herlihy B; Meng J; Chupikova I; Tao J; Ghosh N; Dutta RK; Kolli U; Yan Y; Valdes E; Sharma M; Sharma U; Moidunny S; Roy S
    J Neuroimmune Pharmacol; 2022 Jun; 17(1-2):76-93. PubMed ID: 34993905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut-Microbiome Implications in Opioid Use Disorder and Related Behaviors.
    Herlihy B; Roy S
    Adv Drug Alcohol Res; 2022; 2():10311. PubMed ID: 38390617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the impact of the gut microbiome on opioid use disorder: Pathways, mechanisms, and treatment insights.
    Kazemian N; Pakpour S
    Microb Biotechnol; 2024 Oct; 17(10):e70030. PubMed ID: 39388360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid trail: Tracking contributions to opioid use disorder from host genetics to the gut microbiome.
    Duffy EP; Bachtell RK; Ehringer MA
    Neurosci Biobehav Rev; 2024 Jan; 156():105487. PubMed ID: 38040073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
    O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
    Drug Alcohol Depend; 2021 Apr; 221():108555. PubMed ID: 33596496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglia: Immune Regulators of Neurodevelopment.
    Cowan M; Petri WA
    Front Immunol; 2018; 9():2576. PubMed ID: 30464763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced gut microbiome protects from alcohol-induced neuroinflammation and alters intestinal and brain inflammasome expression.
    Lowe PP; Gyongyosi B; Satishchandran A; Iracheta-Vellve A; Cho Y; Ambade A; Szabo G
    J Neuroinflammation; 2018 Oct; 15(1):298. PubMed ID: 30368255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Gut Microbiome and Substance Use Disorder.
    Russell JT; Zhou Y; Weinstock GM; Bubier JA
    Front Neurosci; 2021; 15():725500. PubMed ID: 34531718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphine mediates a proinflammatory phenotype via μ-opioid receptor-PKCɛ-Akt-ERK1/2 signaling pathway in activated microglial cells.
    Merighi S; Gessi S; Varani K; Fazzi D; Stefanelli A; Borea PA
    Biochem Pharmacol; 2013 Aug; 86(4):487-96. PubMed ID: 23796752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
    O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
    Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment utilization among persons with opioid use disorder in the United States.
    Wu LT; Zhu H; Swartz MS
    Drug Alcohol Depend; 2016 Dec; 169():117-127. PubMed ID: 27810654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-Seeking Behaviors and Alters the Gut Microbiome.
    Hakimian JK; Dong TS; Barahona JA; Lagishetty V; Tiwari S; Azani D; Barrera M; Lee S; Severino AL; Mittal N; Cahill CM; Jacobs JP; Walwyn WM
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31416242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyloxyacyl hydrolase regulates microglia-mediated pelvic pain.
    Rahman-Enyart A; Yaggie RE; Bollinger JL; Arvanitis C; Winter DR; Schaeffer AJ; Klumpp DJ
    PLoS One; 2022; 17(8):e0269140. PubMed ID: 35980963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
    Baby N; Patnala R; Ling EA; Dheen ST
    Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.